Abstract
Abstract
Eosinophilic pneumonia secondary to drug exposure is a recognized but infrequent complication associated with a variety of medications, including oncological therapies. Among immunomodulatory drugs, pulmonary toxicity has been described for thalidomide and lenalidomide but remains a rare complication.
Pomalidomide is a third-generation immunomodulatory agent used in relapsed or refractory multiple myeloma. It has been authorized in Europe since 2013. To date, only a limited number of cases of pomalidomide-induced lung injury, and even fewer cases of eosinophilic pneumonia, have been documented in the literature.
We present a case of eosinophilic pneumonia attributed to pomalidomide in a 67-year-old patient receiving daratumumab, pomalidomide, and dexamethasone for relapsed multiple myeloma. The diagnosis was supported by compatible respiratory symptoms and imaging, bronchoalveolar lavage eosinophilia, exclusion of alternative causes, lack of clinical improvement with empirical antibiotics, and rapid improvement after pomalidomide withdrawal and systemic corticosteroid therapy.
Prompt recognition of this rare adverse event, discontinuation of pomalidomide, and corticosteroid therapy resulted in rapid clinical and radiological improvement, with sustained pulmonary function recovery at 12-month follow-up.